Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial

BACKGROUND: A new supraglottic device, the LMA-Supreme™, has recently become available for clinical use. Information on anaesthetic and co-adjuvant requirements for insertion of the LMA-Supreme™ is limited. The present study aimed to evaluate the optimal effect-site concentration of propofol in 50 %...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaballos, Matilde, Bastida, Emilia, Agustí, Salomé, Portas, Maite, Jiménez, Consuelo, López-Gil, Maite
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595052/
https://www.ncbi.nlm.nih.gov/pubmed/26438179
http://dx.doi.org/10.1186/s12871-015-0115-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595052/
https://www.ncbi.nlm.nih.gov/pubmed/26438179
http://dx.doi.org/10.1186/s12871-015-0115-8

Ejemplares similares